Mechanisms of Therapeutic Resistance in Prostate Cancer

Mary Nakazawa, Channing Paller, Natasha Kyprianou

Research output: Contribution to journalReview articlepeer-review

Abstract

Prostate cancer is the second leading cause of cancer deaths in the USA. The challenge in managing castration-resistant prostate cancer (CRPC) stems not from the lack of therapeutic options but from the limited duration of clinical and survival benefit offered by treatments in this setting due to primary and acquired resistance. The remarkable molecular heterogeneity and tumor adaptability in advanced prostate cancer necessitate optimization of such treatment strategies. While the future of CRPC management will involve newer targeted therapies in deliberately biomarker-selected patients, interventions using current approaches may exhibit improved clinical benefit if employed in the context of optimal sequencing and combinations. This review outlines our current understanding of mechanisms of therapeutic resistance in progression to and after the development of castration resistance, highlighting targetable and reversible mechanisms of resistance.

Original languageEnglish (US)
Article number13
JournalCurrent oncology reports
Volume19
Issue number2
DOIs
StatePublished - Feb 1 2017

Keywords

  • Castration-resistant prostate cancer
  • Prostate cancer
  • Therapeutic resistance

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Mechanisms of Therapeutic Resistance in Prostate Cancer'. Together they form a unique fingerprint.

Cite this